Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of hyperlipidaemia.

Nigel Stocks1, James Allan, Peter R Mansfield

  • 1Department of General Practice, University of Adelaide, South Australia. nigel.stocks@adelaide.edu.au

Australian Family Physician
|June 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term systolic blood pressure time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.

American journal of hypertension·2026
Same author

Aerosol interplay with meteorology in a biodiversity-rich high-altitude site in India: impacts of southwest monsoon on aerosol chemical characteristics.

Scientific reports·2026
Same author

Can general practitioners use smoking status data in electronic health records to recruit patients for lung cancer screening? A descriptive study using the MedicineInsight database.

BMC primary care·2026
Same author

Sociodemographic and clinical determinants of general practice consultation frequency among regular patients in Australia: a national study.

BJGP open·2026
Same author

Cognitive Decline Preceding Incident Cardiovascular Events in Older Adults.

JAMA network open·2026
Same author

An innovative approach to characterizing the refractive indices and effective densities of internally mixed light-absorbing aerosol particles.

Aerosol science and technology : the journal of the American Association for Aerosol Research·2026

Statins effectively reduce mortality and cardiovascular events in men with established coronary heart disease (CHD). Evidence also supports their use in older men, women with CHD, and high-risk individuals, with infrequent serious side effects.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Hyperlipidaemia, characterized by elevated plasma lipids, is a significant risk factor for coronary heart disease (CHD).
  • Cholesterol-lowering medications, primarily statins, represent a substantial and growing portion of Australia's pharmaceutical expenditure.
  • Primary hypercholesterolaemia warrants focused attention due to its link with cardiovascular disease.

Purpose of the Study:

  • To examine the relationship between primary hypercholesterolaemia and coronary heart disease (CHD).
  • To review the management of hypercholesterolaemia in community settings.
  • To evaluate the efficacy and safety of statin therapy.

Main Methods:

  • Review of existing evidence on statin therapy for hypercholesterolaemia and CHD.

Related Experiment Videos

  • Analysis of treatment benefits across different patient demographics and risk profiles.
  • Assessment of drug discontinuation rates and adverse event occurrences.

    • Main Results:

    • Strong evidence supports statin use in middle-aged men with established CHD, reducing mortality and morbidity.
    • Weaker but reasonable evidence supports statin use in older men, women with CHD, and high-risk individuals without diagnosed CHD.
    • Potential benefits extend to patients with stroke and peripheral vascular disease at risk for CHD.

    Conclusions:

    • Statin therapy offers significant benefits for specific patient groups at risk of or with established cardiovascular disease.
    • While discontinuation rates are notable, serious adverse reactions to statins are infrequent.
    • Management strategies should consider individual patient risk and potential benefits of lipid-lowering therapy.